Musashi-2 (MSI2). MSI1 and MSI2 share approximately 75% amino acid identity in their overall structure and belong to a family of RNA-binding proteins. 18 MSI2 post-transcriptionally regulates mRNA processing by binding to the recognition motifs located at the 3′UTR of target mRNAs, similar to MSI1. MSI2 preferentially interacts with an ACCUUUUUAGAA motif and other poly-U sequences, 19 UAG motifs, and UAG-containing motifs ± additional flanking nucleotides. 20, 21 The Musashi proteins were first linked to cancer based on studies showing elevated expression of MSI1 in gliomas, 22 medulloblastomas, 23 and hepatomas. 24 MSI2 was identified as part of a translocation event with HoxA9 in chronic myeloid leukemias that preserved MSI2 RNA-binding motifs, 25 also implicating MSI2 in cancer development. The past several years have been marked by a surge of reports elucidating the frequency and mechanisms of involvement of MSI2, in particular, in multiple forms of human cancer, 19, [26] [27] [28] including BC. 29 Like MSI1, moreover, Dong et al 30 reported that MSI2 is directly regulated in a negative way by miR-143.
In the present study, we clarified the correlation between 
| MATERIAL S AND ME THODS

| RNA immunoprecipitation
RNA immunoprecipitation (RIP) was carried out with a RIP-assay Kit (Medical & Biological Laboratories Co., Ltd., Aichi, Japan) according to the manufacturer's instructions.
| RNA-stability measurements
The RNA polymerase II transcriptional inhibitor 5,6-dichlorobenzimidazole riboside (DRB) was procured from Tokyo Chemical Industry (Tokyo, Japan). T24 cells were seeded on the day prior to transfection with the cDNA plasmid encoding MSI2 or control vector. The cells were treated with DRB at 24 hours after transfection. Cellular RNA was harvested at time 0, 2, 4, 6 and 8 hours and used for qRT-PCR analysis of KRAS mRNA. RNA half-lives were calculated from linear regression of log-transformed expression values. 31 ANCOVA was carried out on the resulting regression lines to assess statistical significance.
| Human tumor xenograft model
Animal experimental protocols were approved by the Committee Other methods are shown in Data S1.
| RE SULTS
| Impact of KRAS on proliferation of bladder cancer cell lines
To investigate the function of KRAS as an oncogene in human BC, we first assessed the association between cell growth and KRAS and that between it and HRAS in BC cell lines T24 and 253JB-V.
Knockdown of HRAS by use of siRNA significantly suppressed cell proliferation, and knockdown of KRAS resulted in a more potent growth inhibition than that obtained with knockdown of HRAS ( Figure 1A ). In addition, KRAS effector signaling proteins, AKT and ERK1/2, were downregulated by both knockdowns ( Figure 1B ). Of note, this knockdown was more prominent in T24 cells, which have an HRAS mutation, not a KRAS one. These results suggested that KRAS contributed considerably to cell proliferation in BC, as did HRAS.
| Syn-miR-143 directly silences the key genes of KRAS networks and MSI2
Previously, we reported that miR-143 inhibited cell proliferation with apoptosis through silencing PI3K/AKT and MAPK signaling pathways, which are major growth-related effector signal pathways in KRAS networks in BC. 17, 32 As shown in Figure 2A , the expression levels of miR-143 were extremely downregulated in both T24 and 253JB-V cells. Recently, we developed a chemically modified miR-143 that has potent RNase-resistant anticancer activity ( Figure S1 ). This syn-miR-143 silences not only KRAS but also KRAS effector signaling molecules, AKT and ERK. 
| Musashi-2 is upregulated in clinical tumor samples of BC
We examined the expression of MSI2 in 10 samples from BC patients by western blot analysis. Clinicopathological findings of the patients are shown in Table S1 . As shown in Figure 
| Relationship between MSI2 and KRAS or HRAS in T24 cells
To examine the interaction between MSI2 and KRAS, we carried out knockdown and overexpression of MSI2 by using siRNA ( Figure S4 IgG or MSI2 fractions. These data suggested that MSI2 directly bound to KRAS but not to HRAS. Therefore, the data on HRAS observed in Figure 4A ,B were supposedly as a result of an indirect impact of MSI2.
In addition, to determine the direct interaction between MSI2
and KRAS mRNA, we cloned the predicted MSI2 binding site UAGUA in the 3′UTR region of KRAS mRNA in a reporter plasmid vector (
Figure 5B). Results of the luciferase reporter assay indicated that activity of wild-type pMIR-KRAS was decreased by siR-MSI2 compared with that obtained with control siRNA, indicating that the activity paralleled the level of MSI2 protein expression. On the contrary, decrease in the activity of the pMIR vector was almost canceled when the mutated MSI2 binding site AUCAU was used. Thus, these data clearly showed the promoting roles of MSI2 in the translation step of luciferase mRNAs.
To examine direct interaction between MSI2 and UAGUA, we next used the SPR assay. To this end, a recombinant MSI2 protein containing the two RNA-binding domains was expressed ( Figure S5) and immobilized on a sensor-chip surface. A synthetic 15-mer KRAS mRNA containing UAGUA or its scrambled sequence as a control was injected over the sensor chip. As shown in the left panel of Figure 5C , the UAGUA sequence gave the highest binding response to the immobilized MSI2 (reaching 50 resonance units at 10 μmol/L).
In addition, a dissociation constant (K d ) of UAGUA for MSI2 was 2-5-fold lower than that for the control RNA (right panel of Figure 5C ), suggesting that MSI2 preferentially bound to the UAGUA sequence.
Collectively, these data showed that MSI2 directly interacted with KRAS mRNA by recognizing and binding to one of the specific UAGUA sequences. stability or translation of target mRNAs. 33 To determine whether MSI2 could regulate the stability of KRAS mRNA, we estimated the rate of mRNA decay after treatment with DRB. Time-course RNA decay curves for KRAS mRNA were prepared from qRT-PCR data after DRB treatment of cells transfected with pF5A-control or pF5A-MSI2. As a result, the half-life of KRAS mRNA was not significantly changed in either case, whereas overexpression of MSI2 was achieved in the case of pF5A-MSI2 transfection ( Figure 6B ). These data thus showed that MSI2 functioned to enhance the translation of KRAS mRNA rather than to stabilize the mRNA, the finding of which is well supported by the results given in Figure 4A ,B. To further validate that MSI2 regulated the translation, we assessed the expression of translational initiator eIF4E by western blot analysis. Notably, knockdown of MSI2 induced the downregulation of eIF4E ( Figure 6C ). These data suggested that MSI2 played a role in enhancing translation. Furthermore, western blot analysis showed that MSI2 and KRAS were co-upregulated in six cases of 10 clinical BC samples compared with their expression in normal bladder tissues ( Figure 6D ). In Lee's cohort, 34 there was a significant positive correlation of mRNA expression levels between MSI2 and KRAS in human BC ( Figure 6E ). These data suggested that the patients, which had abundant MSI2 mRNA, could have increment of KRAS protein 
| MicroRNA-143/MSI2/KRAS cascade on T24 cell-xenografted tumors in nude mice
We have clarified the novel miR-143/MSI2/KRAS cascade in vitro. To further validate the cascade between miR-143, MSI2 and KRAS, we examined the antitumor effect by using syn-miR-143 and siR-MSI2 
| D ISCUSS I ON
In the current study, we clarified a novel network operating miR-143, MSI2 and KRAS ( Figure 7 ). We were also able to show that the expression of KRAS was affected by MSI2 through binding of the latter to KRAS mRNA, the finding of which was validated by RNA-IP, SPR, and the expression profiles of the genes involved.
Previously, we showed that miR-143 directly silences KRAS signaling networks; 10,17 and Dong et al 30 reported that miR-143 also targets RNA-binding protein MSI2. However, the association between these targets of miR-143, KRAS and MSI2 had not been previously reported. Given the earlier reports that MSI2 has been suggested to interact preferentially with the UAG-containing motifs in the 3′UTR region of its target RNAs, 21,35-37 we predicted the binding site in KRAS mRNA to be UAGUA and showed by a using luciferase reporter assay and the SPR technique ( Figure 5B,C) that MSI2 protein preferentially binds to the sequence. In addition, it was earlier reported that MSI2 has functions to affect the stabilization or translation of its target mRNAs. We demonstrated an association between the specific sequence UAGUA and the ability of MSI2 to enhance the translation of its target mRNA. However, the SPR technique showed that the control sequences, despite the absence of a UAG motif, gave a weak binding response to MSI2 protein ( Figure 5C ). These data suggested that the specificity of MSI2 binding to transcripts may not be so high. The impact of MSI2 on its target RNAs could be due not only to binding ability, but also to other mechanisms. The two RNA recognition motif (RRM) of MSI2 are possibly involved in the mechanism. Biochemical and structural studies have suggested that RRM1 contributes the majority of the binding energy and specificity, whereas RRM2 has a more supportive role. 37 In addition,
Bennett et al 21 reported that these two RRM may provide a mechanism for MSI2 to distinguish its veritable targets. However, this machinery is presently barely understood and further validation is warranted.
In the present study, we clarified that MSI2 directly targeted KRAS, promoting translation of its mRNA. The RTK/RAS pathway has been reported to be involved in the regulation of cell proliferation in several cancers. [42] [43] [44] [45] Recent precision medicine studies showed that gene alterations in RTK/RAS pathways occurred in up to 60% of BC patients. 46 Among these signaling pathways, in particular, up to 80% of non-muscle invasive BC (NMIBC) harbor activating point mutations in FGFR3, 47, 48 which activate the RAS/MAPK pathway. 4, 5, 49 Moreover, the alteration of KRAS occurs more frequently than that of HRAS. nuclear KRAS transcription. 10 As shown in Figure S7 , this cascade was also seen in BC cell lines and, again, the "positive circuit" also occurred in 17, 32 In an earlier study, we also showed that miR-143 directly targets KRAS signaling networks. 10 Furthermore, it was reported that miR-143 also directly targets MSI2 in cervical cancer. 30 In the present study, we clarified the novel association 
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